Literature DB >> 17699847

The development and characterization of a human midgut carcinoid cell line.

George Van Buren1, Asif Rashid, Anthony D Yang, Eddie K Abdalla, Michael J Gray, Wenbiao Liu, Ray Somcio, Fan Fan, E Ramsay Camp, James C Yao, Lee M Ellis.   

Abstract

PURPOSE: Gastrointestinal neuroendocrine tumors (NET) are rare heterogeneous tumors that hypersecrete neuropeptides. The scarcity of good gastrointestinal NET models has limited the ability to study potential therapeutic agents. We describe and characterize the establishment of a human midgut carcinoid tumor cell line carcinoid tumor 2 (CNDT2). EXPERIMENTAL
DESIGN: Tumor cells (CNDT2) were isolated from a liver metastasis from a patient with a primary ileal carcinoid. After 9 weeks in culture, the cells were plated in soft agar, and cells from a single colony were put back in culture (CNDT2.1). Those CNDT2.1 cells were injected s.c. into nude mice. Cells were isolated from a single resultant tumor (CNDT2.5), cultured, and characterized by electron microscopy, reverse transcription-PCR, serotonin enzyme immunoassay, Western blotting, and immunohistochemical analysis for NET markers and potential therapeutic targets.
RESULTS: CNDT2 cells grew in monolayers in vitro, formed colonies in soft agar, and formed tumors in mice. Electron microscopy revealed round, pleomorphic, electron-dense neurosecretory granules characteristic of NETs. Tumor xenografts exhibited the appearance of NETs with small "salt-and-pepper" nuclei on H&E staining and chromogranin A, synaptophysin, and CD56 on immunohistochemical staining. CNDT2.5 cells produced serotonin and expressed insulin-like growth factor receptor-I, platelet-derived growth factor receptor-beta, vascular endothelial growth factor receptor-1, cMET, epidermal growth factor receptor, neuropilin-1, and somatostatin receptors 1 to 5. Cytogenetic analysis revealed the presence of deletions at 2p and 6q and numerous translocations.
CONCLUSION: The establishment of this human midgut carcinoid tumor cell line may serve as a useful model system for studying cell biology and novel targeted agents in preclinical models.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17699847     DOI: 10.1158/1078-0432.CCR-06-2723

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  25 in total

1.  Adenovirus with hexon Tat-protein transduction domain modification exhibits increased therapeutic effect in experimental neuroblastoma and neuroendocrine tumors.

Authors:  Di Yu; Chuan Jin; Justyna Leja; Nadim Majdalani; Berith Nilsson; Fredrik Eriksson; Magnus Essand
Journal:  J Virol       Date:  2011-09-28       Impact factor: 5.103

2.  Identification of cancer stem cells in human gastrointestinal carcinoid and neuroendocrine tumors.

Authors:  Puja Gaur; Eric L Sceusi; Shaija Samuel; Ling Xia; Fan Fan; Yunfei Zhou; Jia Lu; Federico Tozzi; Gabriel Lopez-Berestein; Pablo Vivas-Mejia; Asif Rashid; Jason B Fleming; Eddie K Abdalla; Steven A Curley; Jean-Nicolas Vauthey; Anil K Sood; James C Yao; Lee M Ellis
Journal:  Gastroenterology       Date:  2011-07-30       Impact factor: 22.682

3.  Molecular mechanisms underlying application of serum procalcitonin and stool miR-637 in prognosis of acute ischemic stroke.

Authors:  You-Mei Li; Xue-Yuan Liu
Journal:  Am J Transl Res       Date:  2016-10-15       Impact factor: 4.060

4.  Azacytidine induces cell cycle arrest and suppression of neuroendocrine markers in carcinoids.

Authors:  Vinita M Alexander; Madhuchhanda Roy; Kristen A Steffens; Muthusamy Kunnimalaiyaan; Herbert Chen
Journal:  Int J Clin Exp Med       Date:  2010-03-28

5.  Protein kinase Cδ inactivation inhibits cellular proliferation and decreases survival in human neuroendocrine tumors.

Authors:  Zhihong Chen; Lora W Forman; Kenneth A Miller; Brandon English; Asami Takashima; Regine A Bohacek; Robert M Williams; Douglas V Faller
Journal:  Endocr Relat Cancer       Date:  2011-12-01       Impact factor: 5.678

6.  Accomplishments in 2008 in the management of gastrointestinal neuroendocrine tumors.

Authors:  Matthew H Kulke; Hans Scherübl
Journal:  Gastrointest Cancer Res       Date:  2009-09

7.  QGP-1 cells release 5-HT via TRPA1 activation; a model of human enterochromaffin cells.

Authors:  Hitoshi Doihara; Katsura Nozawa; Ryosuke Kojima; Eri Kawabata-Shoda; Toshihide Yokoyama; Hiroyuki Ito
Journal:  Mol Cell Biochem       Date:  2009-06-09       Impact factor: 3.396

8.  Establishment and Characterization of Small Bowel Neuroendocrine Tumor Spheroids.

Authors:  Po Hien Ear; Guiying Li; Meng Wu; Ellen Abusada; Andrew M Bellizzi; James R Howe
Journal:  J Vis Exp       Date:  2019-10-14       Impact factor: 1.355

9.  Oncolytic vesicular stomatitis virus as a treatment for neuroendocrine tumors.

Authors:  Reese W Randle; Scott A Northrup; S Joseph Sirintrapun; Douglas S Lyles; John H Stewart
Journal:  Surgery       Date:  2013-08-22       Impact factor: 3.982

10.  The somatostatin analogue octreotide inhibits growth of small intestine neuroendocrine tumour cells.

Authors:  Su-Chen Li; Cécile Martijn; Tao Cui; Ahmed Essaghir; Raúl M Luque; Jean-Baptiste Demoulin; Justo P Castaño; Kjell Öberg; Valeria Giandomenico
Journal:  PLoS One       Date:  2012-10-31       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.